AI is boosting biotech stocks like Intuitive Surgical and Recursion Pharmaceuticals, with positive outlooks

From Nasdaq: 2024-07-10 08:34:01

Artificial intelligence (AI) is revolutionizing healthcare and biotech industries, driving advancements in medical research, diagnosis, drug discovery, and personalized medicine. Companies like Intuitive Surgical (ISRG) and Recursion Pharmaceuticals (RXRX) are poised for long-term success.

Intuitive Surgical (ISRG) leads the robotic-assisted minimally invasive surgery market with its da Vinci Surgical System. The company reported a 79.8% market share and a stock surge of 31.1% YTD. Analysts predict revenue growth of 12.7% in 2024 and anticipate ISRG’s profits to increase by 9.9% to $6.28 per share.

Recursion Pharmaceuticals (RXRX) uses advanced AI and machine learning to accelerate drug discovery. The company’s AI-driven platform, Recursion Operating System (OS), aims to reduce drug development time and costs significantly. RXRX stock has dipped 24.5% YTD, but analysts see a potential upside of 72.4% over the next 12 months.



Read more at Nasdaq: AI Could Power Up These 2 Biotech Stocks